Notes
2017 US dollars
Reference
Correction to: Gemcitabine regimens cost effective for pancreatic cancer. PharmacoEconomics and Outcomes News : No. 809, 11 Aug 2018
Rights and permissions
About this article
Cite this article
Correction to: Gemcitabine regimens cost effective for pancreatic cancer. PharmacoEcon Outcomes News 809, 13 (2018). https://doi.org/10.1007/s40274-018-5165-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5165-y